Replimune Prices $150M Offering at $12.06, Shares Surge 15%
REPL has more than doubled off its 52-week low of $1.5.
Summary
Replimune priced its underwritten offering of 9.7 million shares at $12.06, raising approximately $150 million. The stock jumped 15% to $13.81, reflecting strong demand and a premium to the offer price. This follows the FDA accelerated approval of TUDRIQEV just three days ago, a major catalyst that likely boosted investor appetite. The capital infusion addresses the going concern warning from the June 10-K, extending the cash runway well beyond Q1 2027. The offering is expected to close August 11.
At the time of this announcement, REPL was trading at $13.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $1.50 to $14.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.